Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F2trans-isoprostane in hypercholesterolaemic patients

摘要

What is already known about this subject class="unordered" style="list-style-type:disc">Isoprostanes are the product of free radical oxidation of arachidonic acid bound to phospholipids.Their hydrolysis from phospholipids is presumably catalysed by phospholipases A2.Atorvastatin reduces protein concentrations of secretory PLA2s and concentrations of LDL, with which PAF-AH (group VII phospholipase) is associated.What this study adds class="unordered" style="list-style-type:disc">Atorvastatin affects PAF-AH activity and this effect is strongly associated with its lipid-lowering effect, but it has no effect on groups IIA and V PLA2s' activity.Thus, PAF-AH is no independent risk factor of cardiovascular diseases.Moreover, a role of PAF-AH in the liberation of 15-F2t-isoP from phospholipids is excluded.AimsIsoprostanes are the product of free radical oxidation of arachidonic acid, whose hydrolysis from phospholipids is presumably catalysed by phospholipases A2 (PLA2s) such as group IIA or V PLA2s, or group VII PLA2 [platelet-activating factor acetylhydrolase (PAF-AH), lipoprotein-associated phospholipase]. Atorvastatin reduces concentrations of low-density lipoprotein (LDL), with which PAF-AH is associated, and PLA2s' protein concentrations. We investigated the effect of atorvastatin on PLA2s and PAF-AH activity and the urinary excretion of 15-F2trans-isoprostane (15-F2t-IsoP, 8-iso-PGF2α, iPF2α-III).